Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho’s Jared Holz

August 30, 2024
Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho’s Jared HolzUpside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho’s Jared Holz

Jared Holz, Mizuho, joins ‘Fast Money’ to talk opportunities in pharma investing following approval of Emergent Bio’s Mpox vaccine.


 

Share This

Latest Mizuho News

Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein

Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein

November 18, 2025
VR has been ‘pretty big disappointment’ for Meta, says Mizuho’s Lloyd Walmsley

VR has been ‘pretty big disappointment’ for Meta, says Mizuho’s Lloyd Walmsley

December 4, 2025
Walmart lifts full-year outlook, warns of higher costs

Walmart lifts full-year outlook, warns of higher costs

November 20, 2025

Mizuho news from around the globe

back-to-top-blue